Jazz Pharmaceuticals (NASDAQ: JAZZ) reported Q3 EPS of $5.17, $0.51 better than the analyst estimate of $4.66. Revenue for the quarter came in at $940.65 million versus the consensus estimate of $939.97 million.

GUIDANCE:

Jazz Pharmaceuticals raises FY2022 revenue midpoint to $3.65 billion, versus the consensus of $3.65 billion.

For earnings history and earnings-related data on Jazz Pharmaceuticals (JAZZ) click here.